This morning we watched Series rise 1.0% to a price of $75.16 per share. The Large-Cap Medical Instruments & Supplies company is now trading -7.31% below its average target price of $81.08. Analysts have set target prices ranging from $60.0 to $100.0 per share for Series, and have given the stock an average rating of hold.
Series's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.4%. The stock's short ratio is 5.38. The company's insiders own 15.04% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 75.9%. In conclusion, we believe there is mixed market sentiment regarding Series.
Institutions Invested in Series
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2026-03-31 | Independent Franchise Partners, LLP | 9% | 15,733,495 | $1,182,450,797 |
| 2026-03-31 | Blackrock Inc. | 6% | 10,478,972 | $787,547,127 |
| 2026-03-31 | Vanguard Capital Management LLC | 6% | 9,601,949 | $721,634,465 |
| 2025-12-31 | Trian Fund Management, LP | 5% | 8,236,753 | $619,033,161 |
| 2026-03-31 | Vanguard Portfolio Management LLC | 4% | 6,390,364 | $480,267,798 |
| 2025-12-31 | State Street Corporation | 4% | 6,344,761 | $476,840,505 |
| 2026-03-31 | Davis Selected Advisers | 4% | 6,330,325 | $475,755,567 |
| 2025-12-31 | Geode Capital Management, LLC | 3% | 4,588,728 | $344,865,847 |
| 2026-03-31 | Boston Partners | 2% | 3,914,091 | $294,163,504 |
| 2026-03-31 | Invesco Ltd. | 2% | 3,789,883 | $284,828,652 |
